Radiopharm Theranostics (RADX) Short term Debt (2024 - 2025)
Radiopharm Theranostics (RADX) reported Short term Debt of $3.4 million for Q2 2025, down 45.86% year-over-year from $6.3 million in Q2 2024, and down 45.86% quarter-over-quarter from $6.3 million in Q2 2024.
Radiopharm Theranostics (RADX) Short term Debt (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has 2 years of Short term Debt data on file, last reported at $3.4 million in Q2 2025.
- Short term Debt for Q2 2025 came in at $3.4 million, down 45.86% year-over-year; the trailing twelve-month figure through Jun 2025 was $3.4 million (down 45.86% YoY), and the FY2025 annual result was $3.4 million, down 45.86% from the prior year.
- Short term Debt fell to $3.4 million in Q2 2025 per RADX's latest filing, from $6.3 million in the prior quarter.
- Over five years, Short term Debt peaked at $6.3 million in Q2 2024 and troughed at $3.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Radiopharm Theranostics | 5.82 Bn | 5.81 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.42 Mn |
| Jun 30, 2024 | 6.32 Mn |